Praxis Precision Medicines, Inc. (PRAX)

Over the past six months, Praxis Precision Medicines' stock price has been impacted by several events. Shares surged in October 2025 following Phase 3 success for ulixacaltamide. In December 2025, analyst firms raised their price targets, and Citigroup reaffirmed a "conviction-buy" rating. In January 2026, the company announced plans to submit NDAs for ulixacaltamide and relutrigine, and H.C. Wainwright raised its price target. In February 2026, Wells Fargo initiated coverage with an "equal weight" rating, leading to a modest decline in shares. Overall, the stock price increased by 8.4% since January 1, 2026, with weekly volatility decreasing from 29% to 13% over the past year.

Praxis Precision Medicines, Inc. does not exhibit typical demand seasonality for its products and services. The demand for its product candidates is primarily driven by factors such as the prevalence of the targeted diseases, the progress and outcomes of clinical trials, regulatory approvals, and eventual market access, rather than seasonal consumer patterns.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders. The company operates within the Healthcare sector and Biotechnology industry, utilizing the Cerebrum and Solidus platforms. The Cerebrum platform develops orally available precision therapies, while the Solidus platform is an antisense oligonucleotide discovery and development engine. Praxis's major product candidates include ulixacaltamide for essential tremor, vormatrigine for focal onset epilepsy, relutrigine for developmental and epileptic encephalopathies, PRAX-020, PRAX-050, elsunersen for SCN2A-DEE, PRAX-080 for PCDH19-related developmental epilepsy, PRAX-090 for SYNGAP1 loss-of-function, and PRAX-100 for SCN2A LoF mutations.

Praxis Precision Medicines, Inc. is headquartered in Boston, Massachusetts, United States.

Praxis Precision Medicines has a generally positive brand reputation, particularly among analysts, with a consensus rating of "Moderate Buy". MarketBeat ranked Praxis Precision Medicines higher than 67% of companies evaluated in the medical sector. Analyst sentiment has remained strongly bullish following the Phase 3 success of ulixacaltamide in October 2025. The company is recognized for its innovative approach and scientific rigor in developing therapies for neurological and psychiatric disorders.

As of December 2025, Praxis Precision Medicines, Inc. has 307 institutional owners and shareholders holding a total of 27,343,385 shares. Major institutional owners include Janus Henderson Group Plc, Adage Capital Partners Gp, L.l.c., BlackRock, Inc., Perceptive Advisors Llc, Point72 Asset Management, L.P., Vanguard Group Inc, Price T Rowe Associates Inc /md/, Cormorant Asset Management, LP, State Street Corp and Soleus Capital Management, L.P.. The top institutional stake belongs to Assenagon Asset Management S.A., owning 408.79K shares, or 1.86% of the company. Institutional ownership percentage is 114.15%, while individuals hold 1.11% of the shares.